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PreviewsA Role for RKIP in Cell Motility
The target of locostatin, a small-molecule inhibitor of
cell movement, has been identified as RKIP, a Raf-1 ki-
nase modulator [1]. In addition to advancing our un-
derstanding of cell locomotion, this work represents
a major landmark in the development of chemical ge-
netics.
Cell locomotion is a fundamental feature of many nor-
mal and pathological processes including morphogen-
esis, wound healing, and metastasis. Consequently, a
detailed understanding of cell movement is a major
goal for modern biology and medicine. Crawling cells
move forward due to tightly choreographed interplay
between actin filament assembly and disassembly, mo-
lecular motor-based movement, and differential cell ad-
hesion. To date, we know a considerable amount about
the actomyosin-based machinery and cell adhesion
molecules essential for cell locomotion, and more than
a little about some of the immediate regulators of this
machinery. We do not, however, know much about reg-
ulators farther upstream, except in some systems that
undergo chemotaxis [2]. However, in this issue of
Chemistry & Biology, Zhu et al. report that locostatin,
a small-molecule cell motility inhibitor [3], inhibits cell
migration by covalent modification of RKIP (Raf kinase
inhibitor protein; Figure 1). Because RKIP has no known
direct cytoskeleton or adhesion protein targets, and be-
cause it is a metastasis suppressor [4], it likely repre-
sents a general upstream regulator of cell motility.
The case for RKIP as the locostatin target is very
strong [1]: RKIP is one of only four proteins specifically
bound by locostatin and the only one of the four whose
binding profile for locostatin analogs correlates with the
effects of the analogs on cell locomotion. Further, RKIP
knockdown suppresses cell motility, thus mimicking the
locostatin phenotype, while RKIP overexpression pro-
motes cell migration and reduces the effects of lo-
costatin. Indeed, RKIP overexpression changes the ba-
sic features of epithelial cell growth, causing them to
lose cell-cell adhesions and generally resemble other,
more motile cell types.
How does RKIP function during cell migration? As its
name implies, RKIP is best known as an inhibitor of
Raf-1 [5, 6], a serine/threonine kinase, and Zhu et al.
[1] show that locostatin suppresses RKIP-Raf-1 binding.
Because raf kinases are essential players in cell division
promoted by the small GTPase, ras, RKIP might be sup-
posed to exert its effects through inhibition of cell divi-
sion. However, this is not the case, since cell division is
not required for movement in the assay used by Zhu et
al. and gene knockout experiments indicate that Raf-1 is
not the raf isoform required for ras-dependent cell divi-
sion [7]. A more direct link between Raf-1 and cell loco-
motion comes from the demonstration that Raf-1 can
control cell migration by controlling the localization of an-
other kinase, Rock-α [8]. However, the Raf-1-Rock-α in-teraction is kinase independent, so it’s not clear how inhi-
bition of RKIP, which is expected to result in activation of
Raf-1 kinase activity, suppresses cell locomotion.
An alternative mechanism is suggested by the dem-
onstration that, when phosphorylated by protein kinase
C, RKIP ceases to bind Raf-1, and instead binds to and
inhibits G protein-coupled receptor kinase 2 (GRK2 [9])
(Figure 1). GRK2 is a serine/threonine kinase known to
downregulate a variety of G protein-coupled receptors
[10]. Significantly, such receptors play a key role in cell
locomotion in other cell types [2]. Further, in leukocytes,
increased GRK2 activity is associated with suppression
of cell locomotion [11], while GRK2 loss is correlated with
increased cell locomotion [12]. In this case, the loco-
statin-RKIP interaction would have to disrupt RKIP-GRK2
binding, a point which needs to be tested.
In addition to providing important insight into cell lo-
comotion, this work also fulfills the promise of chemical
genetics as an approach with many of the strengths of
classic genetics, but which is not limited to a few model
systems. To be sure, the chemical genetic approach
can suffer from a relative lack of specificity and re-
duced potency of many small-molecule effectors and,
in many cases, difficulty in cellular target identification.
Nevertheless, this report [1], when considered with the
authors’ previous work [3], satisfies several key criteria
that define a successful genetic study.
First, classic forward genetics can work with any pro-
cess, no matter how complex, as long as an appropri-
ate screen is employed. While much recent effort in
chemical genetics has focused on the use of auto-
mated, high-throughput screens, with a particular bias
toward biochemical readouts [13, 14], here a screen
based on visual inspection of epithelial cell migration
was performed. Manual screens are inherently slower
and less objective than automated screens; however,
they are also simpler and higher content [15], and their
potential for success is confirmed by the identification
of locostatin. Given the relative accessibility of manual
screens to the average investigator, and the fact that
small-molecule libraries can now be obtained commer-
cially, or even for free, it follows that chemical genetics
is an avenue available to anyone who cares to try it.
Second, genetic studies have the potential to identify
any player that controls a particular process, regardless
of that player’s mode of action. However, many pre-
viously identified small-molecule inhibitors target en-
zymes. Further, of those that target nonenzymes by dis-
rupting protein-protein interactions, most, if not all, of
them were identified in screens directed at finding
agents to disrupt binding of two particular proteins
(e.g., Myc and Max; see [13]). Locostatin not only tar-
gets a nonenzyme (RKIP), disrupting the interaction of
RKIP with Raf-1, but was also identified in a target-
blind approach. This indicates that small molecules
may prove generally useful as regulators of nonenzymes
by disrupting protein-protein interactions and, by exten-
sion, that this approach can potentially identify any rele-
vant player in a pathway.
Third, the ideal genetic study is definitive, with a par-
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954Figure 1. Schematic Diagram Showing Relationship of RKIP to Its
Targets and Locostatin
Active RKIP inhibits Raf-1 kinase (Raf1). When RKIP is phosphory-
lated by protein kinase C (PKC), it no longer inhibits Raf-1 but in-
stead inhibits Grk2. The question mark indicates that whether or
not locostatin inhibits phosphorylated RKIP is currently unknown.
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Mticular gene and gene product linked to a phenotype by
mapping (or a related approach) and by rescue. Here,
rather than first narrowing the field to “likely suspects”
and potentially missing unexpected targets, Zhu et al.
[1] took advantage of the fact that locostatin covalently
modifies its targets, and then subjected the entire pro-
teome to labeling with tritiated locostation. Only four
proteins were thus identified, and of these, only RKIP
subsequently satisfied further tests (see above).
Fourth, some of the most useful genetic screens are
for conditional (e.g., temperature-sensitive) mutants,
which permit disruption of a particular protein at the
investigator’s convenience. But conditional mutants can
be hard to come by. Chemical genetics, however, pro-
vides the pharmacological equivalent of a conditional
mutant, in that a drug can be applied at any time. This
is a particular advantage for proteins likely to play mul-
tiple roles during the lifetime of a cell, tissue, or organ-
ism. RKIP, for example, has previously been implicated
not only in cell division, but also in differentiation and
programmed cell death [4, 16]. Thus, simply disrupting
RKIP function by gene knockout in a developing organ-
ism might fail to reveal its role in cell locomotion. Since
most proteins play multiple roles, such pharmacologi-
cal conditionality is a great advantage.
Just how far can functional analogies between chem-
ical genetics and classic genetics be pushed? After the
success of these studies, one can’t help but wonder if
other genetic strategies will work for chemical genetics.
For example, it might be possible to identify other play-
ers that work in the RKIP pathway by screening for
small-molecule suppressors or enhancers of locostatin-
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1ependent inhibition of cell movement. Not only might
uch approaches reveal exactly how RKIP regulates cell
otility, the former also has the potential to identify novel
herapeutic agents, as RKIP levels are sharply reduced in
number of tumors, and it has recently been suggested
hat small molecules that modulate RKIP targets offer a
romising approach for cancer treatment [4, 16].
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